Cargando…

Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates

Penicillin plus ceftriaxone is a promising alternative to ampicillin plus ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis. Limited data is available supporting the utilization of penicillin plus ceftriaxone. A total of 20 E. faecalis isolates; one wild-type strain (JH2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Cusumano, Jaclyn A., Khan, Ruhma, Shah, Zeel, Philogene, Cassie, Harrichand, Amrita, Huang, Vanthida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430804/
https://www.ncbi.nlm.nih.gov/pubmed/35703558
http://dx.doi.org/10.1128/spectrum.00621-22
_version_ 1784779877951471616
author Cusumano, Jaclyn A.
Khan, Ruhma
Shah, Zeel
Philogene, Cassie
Harrichand, Amrita
Huang, Vanthida
author_facet Cusumano, Jaclyn A.
Khan, Ruhma
Shah, Zeel
Philogene, Cassie
Harrichand, Amrita
Huang, Vanthida
author_sort Cusumano, Jaclyn A.
collection PubMed
description Penicillin plus ceftriaxone is a promising alternative to ampicillin plus ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis. Limited data is available supporting the utilization of penicillin plus ceftriaxone. A total of 20 E. faecalis isolates; one wild-type strain (JH2-2) and 19 clinical blood strains were assessed for penicillin plus ceftriaxone and ampicillin plus ceftriaxone synergy using a 24-h time-kill experiment. Susceptibility was determined by broth microdilution. Differences in bactericidal, bacteriostatic, or inactivity, as well as synergy between treatments were assessed by chi-square or Fisher exact test. All E. faecalis isolates were considered susceptible to ampicillin and penicillin. Ampicillin plus ceftriaxone versus penicillin plus ceftriaxone similarly demonstrated synergy. Bactericidal activity was more commonly observed for ampicillin plus ceftriaxone versus penicillin plus ceftriaxone. Among isolates with a penicillin MIC of 4 μg/mL (n = 7), synergistic activity for both combinations was less common compared to isolates with a penicillin MIC ≤ 2 μg/mL (n = 13). Ampicillin plus ceftriaxone and penicillin plus ceftriaxone demonstrate similar synergistic potential against E. faecalis clinical blood isolates, but strains with higher penicillin and ceftriaxone MICs less frequently demonstrated synergy. Further research is warranted to determine the role of the penicillin plus ceftriaxone therapy and the penicillin MIC in clinical practice. IMPORTANCE Penicillin plus ceftriaxone demonstrates similar synergistic activity against Enterococcus faecalis to ampicillin plus ceftriaxone. Isolates with a penicillin MIC of 4 mg/L and a ceftriaxone MIC of 512 or higher, lack penicillin plus ceftriaxone synergy despite the penicillin susceptibility MIC breakpoint of 8 mg/L.
format Online
Article
Text
id pubmed-9430804
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-94308042022-09-01 Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates Cusumano, Jaclyn A. Khan, Ruhma Shah, Zeel Philogene, Cassie Harrichand, Amrita Huang, Vanthida Microbiol Spectr Research Article Penicillin plus ceftriaxone is a promising alternative to ampicillin plus ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis. Limited data is available supporting the utilization of penicillin plus ceftriaxone. A total of 20 E. faecalis isolates; one wild-type strain (JH2-2) and 19 clinical blood strains were assessed for penicillin plus ceftriaxone and ampicillin plus ceftriaxone synergy using a 24-h time-kill experiment. Susceptibility was determined by broth microdilution. Differences in bactericidal, bacteriostatic, or inactivity, as well as synergy between treatments were assessed by chi-square or Fisher exact test. All E. faecalis isolates were considered susceptible to ampicillin and penicillin. Ampicillin plus ceftriaxone versus penicillin plus ceftriaxone similarly demonstrated synergy. Bactericidal activity was more commonly observed for ampicillin plus ceftriaxone versus penicillin plus ceftriaxone. Among isolates with a penicillin MIC of 4 μg/mL (n = 7), synergistic activity for both combinations was less common compared to isolates with a penicillin MIC ≤ 2 μg/mL (n = 13). Ampicillin plus ceftriaxone and penicillin plus ceftriaxone demonstrate similar synergistic potential against E. faecalis clinical blood isolates, but strains with higher penicillin and ceftriaxone MICs less frequently demonstrated synergy. Further research is warranted to determine the role of the penicillin plus ceftriaxone therapy and the penicillin MIC in clinical practice. IMPORTANCE Penicillin plus ceftriaxone demonstrates similar synergistic activity against Enterococcus faecalis to ampicillin plus ceftriaxone. Isolates with a penicillin MIC of 4 mg/L and a ceftriaxone MIC of 512 or higher, lack penicillin plus ceftriaxone synergy despite the penicillin susceptibility MIC breakpoint of 8 mg/L. American Society for Microbiology 2022-06-15 /pmc/articles/PMC9430804/ /pubmed/35703558 http://dx.doi.org/10.1128/spectrum.00621-22 Text en Copyright © 2022 Cusumano et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Cusumano, Jaclyn A.
Khan, Ruhma
Shah, Zeel
Philogene, Cassie
Harrichand, Amrita
Huang, Vanthida
Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
title Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
title_full Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
title_fullStr Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
title_full_unstemmed Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
title_short Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
title_sort penicillin plus ceftriaxone versus ampicillin plus ceftriaxone synergistic potential against clinical enterococcus faecalis blood isolates
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430804/
https://www.ncbi.nlm.nih.gov/pubmed/35703558
http://dx.doi.org/10.1128/spectrum.00621-22
work_keys_str_mv AT cusumanojaclyna penicillinplusceftriaxoneversusampicillinplusceftriaxonesynergisticpotentialagainstclinicalenterococcusfaecalisbloodisolates
AT khanruhma penicillinplusceftriaxoneversusampicillinplusceftriaxonesynergisticpotentialagainstclinicalenterococcusfaecalisbloodisolates
AT shahzeel penicillinplusceftriaxoneversusampicillinplusceftriaxonesynergisticpotentialagainstclinicalenterococcusfaecalisbloodisolates
AT philogenecassie penicillinplusceftriaxoneversusampicillinplusceftriaxonesynergisticpotentialagainstclinicalenterococcusfaecalisbloodisolates
AT harrichandamrita penicillinplusceftriaxoneversusampicillinplusceftriaxonesynergisticpotentialagainstclinicalenterococcusfaecalisbloodisolates
AT huangvanthida penicillinplusceftriaxoneversusampicillinplusceftriaxonesynergisticpotentialagainstclinicalenterococcusfaecalisbloodisolates